

INTERNATIONAL COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 16 December 1997 (16.12.97)	
International application No. PCT/GB97/01250	Applicant's or agent's file reference SMW/BP5610415
International filing date (day/month/year) 08 May 1997 (08.05.97)	Priority date (day/month/year) 08 May 1996 (08.05.96)
Applicant BALL, Kathryn, Lindsay et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

28 November 1997 (28.11.97)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer R. Raissi</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

WALTON, Seán, M.
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP
ROYAUME-UNI

Date of mailing (day/month/year) 20 August 1997 (20.08.97)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference SMW/BP5610415	
International application No. PCT/GB97/01250	International filing date (day/month/year) 08 May 1997 (08.05.97)

1. The following indications appeared on record concerning:

☒ the applicant

 ☐ the inventor

 ☐ the agent

 ☐ the common representative

Name and Address

UNIVERSITY OF DUNDEE
Dundee
DD1 4HN-UNI
United kingdom

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person

 ☐ the name

 ☐ the address

 ☐ the nationality

 ☐ the residence

Name and Address

CYCLACEL LIMITED
Marquis House
67-68 Jermyn Street
London SW1Y 6NY
United kingdom

State of Nationality

State of Residence

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

Please note that a new Power of Attorney is needed. Also, please provide the Nationality and residence of the new applicant.

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input checked="" type="checkbox"/> the designated Offices concerned
<input checked="" type="checkbox"/> the International Searching Authority	<input type="checkbox"/> the elected Offices concerned
<input type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer I. Britel Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

WO 97/42222
PCT/GB97/01250

PCT

From the INTERNATIONAL BUREAU

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:

WALTON, Seán, M.
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP
ROYAUME-UNI

RECEIVED

21 NOV 1997

Date of mailing (day/month/year) 13 November 1997 (13.11.97)		
Applicant's or agent's file reference SMW/BP5610415		
IMPORTANT NOTICE		
International application No. PCT/GB97/01250	International filing date (day/month/year) 08 May 1997 (08.05.97)	Priority date (day/month/year) 08 May 1996 (08.05.96)
Applicant CYCLACEL LIMITED et al		

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
AU, BR, CA, CN, EP, IL, JP, KP, KR, NO, PL, SK, US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AL, AM, AP, AT, AZ, BA, BB, BG, BY, CH, CU, CZ, DE, DK, EA, EE, ES, FI, GB, GE, GH, HU, IS, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, OA, PT, RO, RU, SD, SE, SG, SI, TJ, TM, TR, TT, UA, UG, UZ, VN, YU

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 13 November 1997 (13.11.97) under No. WO 97/42222

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.


The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

Continuation of Form PCT/IB/308

**NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF
THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES**

Date of mailing (day/month/year) 13 November 1997 (13.11.97)	IMPORTANT NOTICE
Applicant's or agent's file reference SMW/BP5610415	International application No. PCT/GB97/01250
<p>The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.</p>	

PATENT COOPERATION TREATY


NOTIFICATION CONCERNING
SUBMISSION OF PRIORITY DOCUMENTS

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

WALTON, Seán, M.
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP
ROYAUME-UNI



Date of mailing (day/month/year)

04 June 1997 (04.06.97)

Applicant's or agent's file reference

SMW/BP5610415

IMPORTANT NOTIFICATION

International application No.

PCT/GB97/01250

International filing date (day/month/year)

08 May 1997 (08.05.97)

Priority date (day/month/year)

08 May 1996 (08.05.96)

Applicant

UNIVERSITY OF DUNDEE et al

The applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to the following application(s):

Priority application No.:

9609521.1

Priority date:

08 May 1996 (08.05.96)

Priority country:

GB

Date of receipt of priority document:

02 Jun 1997 (02.06.97)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

MCG
M.C. Guillemot

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY


PCT

NOTIFICATION CONCERNING
SUBMISSION OF PRIORITY DOCUMENTS

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

WALTON, Seán, M.
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP
ROYAUME-UNI

Date of mailing (day/month/year) 13 June 1997 (13.06.97)		
Applicant's or agent's file reference SMW/BP5610415		
IMPORTANT NOTIFICATION		
International application No. PCT/GB97/01250	International filing date (day/month/year) 08 May 1997 (08.05.97)	Priority date (day/month/year) 08 May 1996 (08.05.96)
Applicant UNIVERSITY OF DUNDEE et al		

The applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to the following application(s):

<u>Priority application No.:</u>	<u>Priority date:</u>	<u>Priority country:</u>	<u>Date of receipt of priority document:</u>
9621314.5	09 Oct 1996 (09.10.96)	GB	10 Jun 1997 (10.06.97)

RECORDS NOTED	_____
COMPUTER ENT'D	_____
REGISTER ENT'D	_____
ALREADY ENT'D	_____
DIARY ENT'D	_____

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer M.C. Guillemot Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

MARKS NOTED: SM
 COMPUTER ENT'D: SM
 REGISTER ENT'D: SM
 ALREADY ENT'D: SM
 PCT

~~Copy sent to SJH~~

From the INTERNATIONAL BUREAU

To:

WALTON, Seán, M.
 Mewburn Ellis
 York House
 23 Kingsway
 London WC2B 6HP
 ROYAUME-UNI



NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and
 Administrative Instructions, Section 422)

Date of mailing (day/month/year) 20 August 1997 (20.08.97)	
Applicant's or agent's file reference SMW/BP5610415	STK IMPORTANT NOTIFICATION
International application No. PCT/GB97/01250	
International filing date (day/month/year) 08 May 1997 (08.05.97)	

1. The following indications appeared on record concerning:

☒ the applicant
 ☐ the inventor
 ☐ the agent
 ☐ the common representative

Name and Address

UNIVERSITY OF DUNDEE
 Dundee
 DD1 4HN-UNI
 United kingdom

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person
 ☐ the name
 ☐ the address
 ☐ the nationality
 ☐ the residence

Name and Address

CYCLACEL LIMITED
 Marquis House
 67-68 Jermyn Street
 London SW1Y 6NY
 United kingdom

State of Nationality

State of Residence

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

Please note that a new Power of Attorney is needed. Also, please provide the Nationality and residence of the new applicant.

4. A copy of this notification has been sent to:

☒ the receiving Office
 ☒ the designated Offices concerned
☒ the International Searching Authority
 ☐ the elected Offices concerned
☐ the International Preliminary Examining Authority
 ☐ other:

The International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer


I. Britel

Telephone No.: (41-22) 338.83.38

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

KIDDLE, Simon J.
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP
GRANDE BRETAGNE



PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing
(day/month/year)

10.08.98

Applicant's or agent's file reference
SJK/BP5610415

IMPORTANT NOTIFICATION

International application No.
PCT/GB97/01250

International filing date (day/month/year)
08/05/1997

Priority date (day/month/year)
08/05/1996

Applicant
CYCLACEL LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. (+49-89) 2399-0. Tx: 523656 epmu d
Fax: (+49-89) 2399-4465

Authorized officer

Heisel. M

Tel. (+49-89) 2399-8051



PATENT COOPERATION TREATY

PCT

19

REC'D 13 AUG 1998

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SJK/BP5610415	FOR FURTHER ACTION		See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)
International application No. PCT/GB97/01250	International filing date (day/month/year) 08/05/1997	Priority date (day/month/year) 08/05/1996	
International Patent Classification (IPC) or national classification and IPC C07K14/47			
Applicant CYCLACEL LIMITED et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of **6** sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of **10** sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 28/11/1997	Date of completion of this report <div style="text-align: center; font-weight: bold;">10.08.98</div>
Name and mailing address of the IPEA/ <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. (+49-89) 2399-0. Tx: 523656 apmu d Fax: (+49-89) 2399-4465 </div> </div>	Authorized officer Stolz, B Telephone No. (+49-89) 2399-3416



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB97/01250

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-78 as originally filed

Claims, No.:

1-36 as received on 24/07/1998 with letter of 24/07/1998

Drawings, sheets:

1/10-10/10 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
- ☐ translation of the earlier application whose priority has been claimed.
2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB97/01250

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 24-28, 34-36.

because:

- ☒ the said international application, or the said claims Nos. 24-28, 34-36 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB97/01250

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims 1-23, 29-33
	No:	Claims
Inventive step (IS)	Yes:	Claims 1-23, 29-33
	No:	Claims
Industrial applicability (IA)	Yes:	Claims 1-23, 29-33
	No:	Claims

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB97/01250

1. Priority

Priority documents have not been available at the time of establishing this report. It has however been established under the assumption of valid priority rights. Should this not hold true, the following documents, cited in the ISR as P-documents, might become important: Ball et al., Current Biology, 1997, vol. 7, no. 1, pp. 71-80; and Chen et al., Mol. Cell. Biol., 1996, vol. 16, no. 9, pp. 4673-4682.

2. No opinion

The subject matter of claims 24 to 28, and 34 to 36 relates to methods for the treatment of the human or animal body. In accordance with Rule 67.1 PCT, an opinion for these claims is not established.

3. Reasoned statement

3.1. Basically, the application discloses regions or segments of p21 important for interaction with cyclin D1 and/or Cdk4. Claimed are (i) methods of identifying compounds interfering with the interaction between p21 and cyclin D1 and/or Cdk4 by using a set of peptides including defined fragments, (ii) the use of those peptides in such screening methods, (iii) the use of p21 fragments or derivatives in the manufacture of medicaments or for medical treatment of cdk4 mediated disease, and (iv) the use of defined p21 fragments in order to interfere with the interaction between p21 and cyclin D1 and/or Cdk4.

3.2. Novelty (Art. 33(2) PCT)

Assays to identify compounds affecting the interaction of p21 with cyclin D1 and/or Cdk4 by using fragments of p21 have not been disclosed in the prior art. Claims 1 to 23 are thus novel. The various uses of p21 fragments of claims 24 to 33 have also not been disclosed in the available prior art.

3.3. Inventive step (Art. 33(3) PCT)

The prior art contains a number of studies to identify domains of p21 important for its interaction with various binding partners. But it is silent with respect to domains important for interaction with cyclin D1 and cdk4. This information cannot be derived from the prior art in an obvious manner. Therefore, also the use of such domains (or fragments) in methods according to claims 1 to 23, and claims 31 to 33, and the defined peptide of claims 29 and 30 cannot be derived from the prior art.

4. Certain observations

- 4.1. Claim 1 as presently worded could also include the use of full-length p21 because p21 could be described as "a substance which includes" one or several of the listed fragments. The prior art describes studies of p21 and mutants thereof with respect to their ability to interact with cyclin D1 and to their ability to affect activity of the cyclin D1/Cdk4 complex. The use of this system to search for interfering compounds is obvious to those of skill.
- 4.2. The term "derivative or analogue" used throughout the claims is vague and renders the scope of the claims unclear.
- 4.3. On several occasions "functional mimetics" are mentioned in the claims without any technical specification. The function which is to be mimicked is not specified, and the application does not provide a single example. Thus, the scope of those claims cannot be unambiguously established. Moreover, even if the function was defined, inventive step would be required to find mimetics of any of the defined peptides.
- 4.4. Claim 9 refers to "a p21 mediated effect on cdk4 activity" without specifying what effect. It seems thus impossible to determine when a method is falling within the scope of claim 9.
The same argument seems to apply to the "cdk4 activity" of claim 14, and "the property of inhibiting cdk4" of claim 29.

PATENT COOPERATION TREATY

PCT


NOTIFICATION OF RECEIPT OF
RECORD COPY

RECORD COPY 2(a)	<i>[Signature]</i>
COMPUTER ENTRY	
REGISTER ENTRY	
ALREADY ENTRY	
DIARY ENTRY	

From the INTERNATIONAL BUREAU

To:

WALTON, Seán, M.
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP
ROYAUME-UNI



Date of mailing (day/month/year) 26 May 1997 (26.05.97)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference SMW/BP5610415	International application No. PCT/GB97/01250

The applicant is hereby notified that the International Bureau has received the record copy of the international application as detailed below.

Name(s) of the applicant(s) and State(s) for which they are applicants:

UNIVERSITY OF DUNDEE (for all designated States except US)
BALL, Kathryn, Lindsay et al (for US)

International filing date : 08 May 1997 (08.05.97)
Priority date(s) claimed : 08 May 1996 (08.05.96)
09 October 1996 (09.10.96)

Date of receipt of the record copy
by the International Bureau : 26 May 1997 (26.05.97)

List of designated Offices :

AP : GH, KE, LS, MW, SD, SZ, UG
EA : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP : AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
OA : BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
National : AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU,
IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU

ATTENTION

The applicant should carefully check the data appearing in this Notification. In case of any discrepancy between these data and the indications in the international application, the applicant should immediately inform the International Bureau.

In addition, the applicant's attention is drawn to the information contained in the Annex, relating to:

- ☒ time limits for entry into the national phase;
☐ confirmation of precautionary designations;
☐ requirements regarding priority documents.

A copy of this Notification is being sent to the receiving Office and to the International Searching Authority.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer: R. Raissi Telephone No. (41-22) 730.91.11
--	---

INFORMATION ON TIME LIMITS FOR ENTERING THE NATIONAL PHASE

The applicant is reminded that the "national phase" must be entered before each of the designated Offices indicated in the Notification of Receipt of Record Copy (Form PCT/IB/301) by paying national fees and furnishing translations, as prescribed by the applicable national laws.

The time limit for performing these procedural acts is **20 MONTHS** from the priority date or, for those designated States which the applicant elects in a demand for international preliminary examination or in a later election, **30 MONTHS** from the priority date, provided that the election is made before the expiry of 19 months from the priority date. Some designated (or elected) Offices have fixed time limits which expire even later than 20 or 30 months from the priority date. In other Offices an extension of time or grace period, in some cases upon payment of an additional fee, is available.

In addition to these procedural acts, the applicant may also have to comply with other special requirements applicable in certain Offices. **It is the applicant's responsibility** to ensure that the necessary steps to enter the national phase are taken in a timely fashion. Most designated Offices do not issue reminders to applicants in connection with the entry into the national phase.

For detailed information about the procedural acts to be performed to enter the national phase before each designated Office, the applicable time limits and possible extensions of time or grace periods, and any other requirements, see the relevant Chapters of Volume II of the PCT Applicant's Guide. Information about the requirements for filing a demand for international preliminary examination is set out in Chapter IX of Volume I of the PCT Applicant's Guide.

Note that since ES is not bound by PCT Chapter II (which provides for the international preliminary examination procedure), that State cannot be elected in a demand for international preliminary examination. In the case of the designation of ES for a national patent, the applicant must thus always enter the national phase before the national Office of that State before the expiration of 20 months from the priority date. In the case of the designation of ES for a European patent, however, the 31-month time limit applies in respect of that designation if at least one other State designated for a European patent is also elected within the 19-month period.*

Note also that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

- * CH and LI became bound by PCT Chapter II on 1 September 1995. GR became bound by PCT Chapter II on 7 September 1996. Therefore, CH and LI may be elected in a demand or a later election filed on or after 1 September 1995, and GR may be elected in a demand or a later election filed on or after 7 September 1996, regardless of the filing date of the international application. (See 2nd paragraph above.)

CONFIRMATION OF PRECAUTIONARY DESIGNATIONS

This notification lists only specific designations made under Rule 4.9(a) in the request. It is important to check that these designations are correct. Errors in designations can be corrected where precautionary designations have been made under Rule 4.9(b). The applicant is hereby reminded that any precautionary designations may be confirmed according to Rule 4.9(c) before the expiration of 15 months from the priority date. If it is not confirmed, it will automatically be regarded as withdrawn by the applicant. There will be no reminder and no invitation. Confirmation of a designation consists of the filing of a notice specifying the designated State concerned (with an indication of the kind of protection or treatment desired) and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.

REQUIREMENTS REGARDING PRIORITY DOCUMENTS

For applicants who have not yet complied with the requirements regarding priority documents the following is recalled.

Where the priority of an earlier national (i.e., national or regional) application is claimed, the applicant must submit a copy of the said national application, certified by the authority with which it was filed ("the priority document") to the receiving Office (which will transmit it to the International Bureau) or directly to the International Bureau, before the expiration of 16 months from the priority date (Rule 17.1).

Where the priority document is issued by the receiving Office, the applicant may, instead of submitting the priority document, request the receiving Office to prepare and transmit the priority document to the International Bureau. Such a request must be made before the expiration of the 16-month time limit.

It is recalled that, where several priorities are claimed, the priority date to be considered for the purposes of computing the 16-month time limit is the filing date of the earliest application whose priority is claimed.

If the priority document concerned is not submitted to the International Bureau before the expiration of the 16-month time limit, or if the request to the receiving Office to transmit the priority document has not been made (and the corresponding fee, if any, paid) before the expiration of this time limit, any designated State may disregard the priority claim.

PATENT COOPERATION TREATY

from the RECEIVING OFFICE

To:

Mewburn Ellis
York House
23 Kingsway
London

WC2B 6HP

22 MAY 1997

PCT

**NOTIFICATION OF THE INTERNATIONAL
APPLICATION NUMBER AND OF THE
INTERNATIONAL FILING DATE**

(PCT Rule 20.5(c))

Date of mailing
(day/month/year)

20/05/97.

Applicant's or agents's file reference
SMW/BP5610415

IMPORTANT NOTIFICATION

International application No.
PCT/GB97/01250

International filing date (day/month/year)
08/05/1997

Priority date (day/month/year)
08/05/1996

Applicant
University of Dundee et al

Title of the invention
Methods and means for inhibition of CDK4 activity

1. The applicant is hereby notified that the international application has been accorded the international application number and the international filing date indicated above.

2. The applicant is further notified that the record copy of the international application:



was transmitted to the International Bureau on

20 MAY 1997.



has not yet been transmitted to the International Bureau for the reason indicated below and a copy of this notification has been sent to the International Bureau*:



because the necessary national security clearance has not yet been obtained.



because (reason to be specified):

* The International Bureau monitors the transmittal of the record copy by the receiving Office and will notify the applicant (with Form PCT/IB/301) of its receipt. Should the record copy not have been received by the expiration of 14 months from the priority date, the International Bureau will notify the applicant (Rule 22.1(c)).

Name and mailing address of the receiving Office

The Patent Office
Cardiff Road, Newport
Gwent NP9 1RH

Facsimile No.

Authorized officer

J. R. LLOYD - THOMAS
ROOM G.Y73 EXT. 4507 4346.

Telephone No.

The demand must be filed directly with the competent International Preliminary Examining Authority if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ _____

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:

The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty.

For International Preliminary Examining Authority use only

Identification of IPEA		Date of receipt of DEMAND
Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or agent's file reference SJK/BP5610415
International application No. PCT/GB97/01250	International filing date (day/month/year) 08/05/1997	(Earliest Priority date (day/month/year)) 8 MAY 1996
Title of invention METHODS AND MEANS FOR INHIBITION OF CDK4 ACTIVITY		
Box No. II APPLICANT(S)		
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) CYCLACEL LIMITED MARQUIS HOUSE 67-68 JERMYN STREET LONDON SW1Y 6NY UNITED KINGDOM		Telephone No.: Facsimile No.: Teleprinter No.:
State (i.e. country) of nationality: GB		State (i.e. country) of residence: GB
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) BALL KATHRYN LINDSAY CRC CELL TRANSFORMATION RESEARCH GROUP DEPARTMENT OF BIOCHEMISTRY UNIVERSITY OF DUNDEE DUNDEE DD1 4HN UNITED KINGDOM		
State (i.e. country) of nationality: GB		State (i.e. country) of residence: GB
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) LANE DAVID PHILIP CRC CELL TRANSFORMATION RESEARCH GROUP DEPARTMENT OF BIOCHEMISTRY UNIVERSITY OF DUNDEE DUNDEE DD1 4HN UNITED KINGDOM		
State (i.e. country) of nationality: GB		State (i.e. country) of residence: GB

☐

Further applicants are indicated on a continuation sheet.

International application No.
PCT/GB97/01250

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The following person ☒ agent ☐ common representative
is:

- and ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.
- ☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.
- ☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

KIDDLE, SIMON J. and others
Mewburn Ellis
York House
23 Kingsway
London WC2B 6HP
GB

Telephone No.:
0171 240 4405

Facsimile No.:
0171 240 9339

Teleprinter No.:
22762 PATENT G

- ☐ Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV STATEMENT CONCERNING AMENDMENTS

The applicant wishes the International Preliminary Examining Authority*

- (i) ☐ to start the international preliminary examination on the basis of the international application as originally filed.
- (ii) ☐ to take into account the amendments under Article 34 of
- ☐ the description (amendments attached).
 - ☐ the claims (amendments attached).
 - ☐ the drawings (amendments attached).
- (iii) ☐ to take into account any amendments of the claims under Article 19 filed with the International Bureau (a copy is attached).
- (iv) ☐ to disregard any amendments of the claims made under Article 19 and to consider them as reversed.
- (v) ☐ to postpone the start of the international preliminary examination until the expiration of 20 months from the priority date unless that Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). *(This check-box may be marked only where the time limit under Article 19 has not yet expired.)*

- * Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed, or where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination, as so amended.

Box No. V ELECTION OF STATES

- ☒ The applicant hereby elects all eligible States *(that is, all States which have been designated and which are bound by Chapter II of the PCT)* except

(If the applicant does not wish to elect certain eligible States, the name(s) or country code(s) of those States must be indicated above.)

International application No.
PCT/GB97/01250

Box No. VI CHECK LIST

The demand is accompanied by the following documents for the purposes of international preliminary examination:

- | | | | |
|--|---|---|--------|
| 1. amendments under Article 34 | | | |
| description | : | 0 | sheets |
| claims | : | 0 | sheets |
| drawings | : | 0 | sheets |
| 2. letter accompanying amendments under Article 34 | : | 0 | sheets |
| 3. copy of amendments under Article | : | 0 | sheets |
| 4. copy of statement under Article | : | 0 | sheets |
| 5. other (<i>specify</i>) | : | 0 | sheets |

For International Preliminary
Examining Authority use only

received not received

<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>

The demand is also accompanied by the item(s) marked below:

- | | |
|--|--|
| 1. <input type="checkbox"/> separate signed power of attorney | 4. <input type="checkbox"/> fee calculation sheet |
| 2. <input type="checkbox"/> copy of general power of attorney | 5. <input checked="" type="checkbox"/> other (<i>specify</i>): |
| 3. <input type="checkbox"/> statement explaining lack of signature | ADDITIONAL REPRESENTATIVES |

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

.....
KIDDLE, SIMON J.
APPOINTED AGENT

For International Preliminary Examining Authority use only

- | | |
|--|---|
| 1. Date of actual receipt of DEMAND: | |
| 2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b): | |
| 3. <input type="checkbox"/> The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply. | <input type="checkbox"/> The applicant has been informed accordingly. |
| 4. <input type="checkbox"/> The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5 | |
| 5. <input type="checkbox"/> Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82. | |

For International Bureau use only

Demand received from IPEA on:

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT" International Application"

Applicant's or agent's file reference SMW/BP5610415
(if desired) (12 characters maximum)

Box No. I TITLE OF INVENTION METHODS AND MEANS FOR INHIBITION OF CDK4 ACTIVITY

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

UNIVERSITY OF DUNDEE
Dundee
DD1 4HN
UNITED KINGDOM

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (i.e. country) of nationality: GB

State (i.e. country) of residence: GB

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

BALL Kathryn Lindsay
CRC Cell Transformation Research Group
Department of Biochemistry
University of Dundee
Dundee DD1 4HN
UNITED KINGDOM

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (if this check-box is marked, do not fill in below.)

State (i.e. country) of nationality: GB

State (i.e. country) of residence: GB

This person is applicant for the purposes of: ☐ all designated ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

WALTON, SEÁN M. and others
MEWBURN ELLIS
YORK HOUSE
23 KINGSWAY
LONDON WC2B 6HP
GB

Telephone No. 0171 240 4405

Facsimile No. 0171 240 9339

Teleprinter No. 22762 PATENT G

☐ Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

If none of the following sub-boxes is used, this sheet is not to be included in the request.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

LANE David Philip
CRC Cell Transformation Research Group
Department of Biochemistry
University of Dundee
Dundee DD1 4HN
UNITED KINGDOM

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only *(if this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality: GB

State (i.e. country) of residence: GB

This person is applicant for the purposes of:

☐ all designated states

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

This person is:

☐ applicant only

☐ applicant and inventor

☐ inventor only *(if this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of:

☐ all designated states

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

This person is:

☐ applicant only

☐ applicant and inventor

☐ inventor only *(if this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of:

☐ all designated states

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

This person is:

☐ applicant only

☐ applicant and inventor

☐ inventor only *(if this check-box is marked, do not fill in below.)*

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of:

☐ all designated states

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No. V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):
Regional Patent

- ☒ **AP** ARIPO Patent: KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA** Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA** OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection desired, specify on dotted line):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BA Bosnia & Herzegovina | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |
| <input checked="" type="checkbox"/> LC St Lucia | |
| <input checked="" type="checkbox"/> LK Sri Lanka | |
| <input checked="" type="checkbox"/> LR Liberia | |
| <input checked="" type="checkbox"/> LS Lesotho | |
| <input checked="" type="checkbox"/> LT Lithuania | |
- Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:
- | |
|---|
| <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> GH Ghana |
| <input checked="" type="checkbox"/> All and any further PCT States not listed |
| <input type="checkbox"/> on this form |

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of
 The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Supplemental Box*If the Supplemental Box is not used, this sheet need not be included in the request.**This box in the following cases:**1. If, in any of the Boxes, the space is insufficient to furnish all the information:**in particular:*

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available;*
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked;*
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America;*
- (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents;*
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "Continuation" or "Continuation-in-part";*
- (vi) if there are more than three earlier applications whose priority is claimed;*

*In such case, write "Continuation of Box No. ..." (indicate the number of the Box) and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient;**in such case, write "Continuation of Box III" and indicate for each additional person the same type of information as required in Box No. III;**in such cases write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;**in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;**in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;**in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;**in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.**2. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty:**in such case, write "Statement Concerning Non-Prejudicial Disclosures or Exceptions to Lack of Novelty" and furnish that statement below.***Continuation of Box IV**

ARMITAGE, IAN M.
 BRASNETT, ADRIAN H.
 BREWSTER, ANDREA R.
 CALDERBANK, T. ROGER
 COLEIRO, RAYMOND
 FORD, MICHAEL F.
 GURA, H. ALAN
 HACKNEY, NIGEL J.
 HAMILTON, ALISTAIR
 HARRISON, DAVID C.
 KIDDLE, SIMON J.
 LINN, S. JONATHAN
 LYONS, JUNE, M.
 NICHOLLS, KATHRYN M.
 O'BRIEN, CAROLINE J.
 PAGET, HUGH C.E.
 SANDERSON, MICHAEL J.
 STONER, G. PATRICK
 STUART, IAN
 WALTON, SEÁN M.

Box No. VI	PRIORITY CLAIM	Further priority claims indicated in the Supplemental Box <input type="checkbox"/>
-------------------	-----------------------	--

The priority of the following earlier application(s) is hereby claimed:

Country (in which, or for which the application was filed)	Filing Date (day/month/year)	Application No.	Office of filing (only for regional or international application)
item (1) GB	8 May 1996 (08/05/96)	9609521.1	
item (2) GB	9 October 1996 (09/10/96)	9621314.5	
item (3)			

Mark the following check-box if the certified copy of the earlier application is to be issued by the Office which for the purposes of the present international application is the receiving Office (a fee may be required):

☒ The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s): (1) & (2)

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (If two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used): ISA/

Earlier search Fill in where a search (international, international-type or other) by the International Searching Authority has already been carried out or requested and the Authority is now requested to base the international search, to the extent possible, on the results of that earlier search. Identify such search or request either by reference to the relevant application (or the translation thereof) or by

Country (or regional Office): Day (day/month/year): Number:

Box No. VIII CHECK LIST

This international application contains the following number of sheets:

1. request	:	5	sheets
2. description	:	78	sheets
3. claims	:	11	sheets
4. abstract	:	1	sheets
5. drawings	:	10	sheets
Total	:	105	sheets


This international application is accompanied by the item(s) marked below:

- | | |
|---|--|
| 1. <input type="checkbox"/> separate signed power of attorney | 5. <input checked="" type="checkbox"/> fee calculation sheet |
| 2. <input type="checkbox"/> copy of general power of attorney | 6. <input type="checkbox"/> separate indications concerning deposited microorganisms |
| 3. <input type="checkbox"/> statement explaining lack of signature | 7. <input type="checkbox"/> nucleotide and/or amino acid sequence listing (diskette) |
| 4. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): | 8. <input type="checkbox"/> other (specify):
Form 23/77 (x2) |

Figure No. 0 of the drawings (if any) should accompany the abstract when it is published.

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request)



BRASNETT, ADRIAN H.

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority specified by the applicant: ISA/	
6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PCT

FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International application No.

Date stamp of the receiving Office

Applicant's or agent's
file reference SMW/BP5610415

Applicant UNIVERSITY OF DUNDEE

CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE.....

£55

T

2. SEARCH FEE

£1003

S

International search to be carried out by _____
 (If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

Basic FeeThe international application contains 105 sheets.

first 30 sheets £328

b

75 x £6 = £450
 remaining sheets additional amount

b

Add amounts entered at b₁ and b₂ and enter total at B....

£778

B

Designation FeesThe international application contains 71 designations.11 x £80 = £880

D

number of designation fees payable (maximum 11) amount of designation fee

Add amounts entered at B and D and enter total at I

£1658

I

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT

£44

P

5. TOTAL FEES PAYABLE

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

£2760

TOTAL

151

☐ The designation fees are not paid at this time.**MODE OF PAYMENT**☐ authorization to charge
deposit account (see below)☐ bank draft☐ coupons☒ cheque☐ cash☐ other (specify)☐ postal money order☐ revenue stamps**DEPOSIT ACCOUNT AUTHORIZATION** (this mode of payment may not be available at all receiving Offices)The RO/ ☐ is hereby authorized to charge the total fee indicated above to my deposit account.☐ is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.☐ is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account.

Deposit Account Number

Day (day/month/year)

Signature

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:
MEWBURN ELLIS
Attn. WALTON, Sean M.
York House
23 Kingsway
London WC2B 6HP
UNITED KINGDOM

RECEIVED
19 SEP 1997

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

[Signature]
PCT Rule 44.1)

Applicant's or agent's file reference SMW/BP5610415	Date of mailing (day/month/year) 17.09.97
International application No. PCT/GB 97/01250	FOR FURTHER ACTION See paragraphs 1 and 4 below International filing date (day/month/year) 08/05/1997
Applicant CYCLACEL LIMITED et al.	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicants's request to forward the texts of both the protest and the decision thereon to the designated Offices.


☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Alfredo Prein
--	--

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference SMW/BP5610415	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 97/ 01250	International filing date(<i>day/month/year</i>) 08/05/1997	(Earliest) Priority Date (<i>day/month/year</i>) 08/05/1996
Applicant CYCLACEL LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☒ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☒ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☒ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. ☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 97/01250

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 31-35, 38-41
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 31-35, 38-41
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/01250

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/47 A61K38/17 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOL.CELL.BIOL., vol. 16, no. 4, April 1996, pages 1786-1793, XP002039986 LIN E.A.: "Anylysis of wild-type and mutant p21(waf1) gene activities" ✓	1-9, 29, 30
Y	The whole document; see especially page1787, column 1	1-3, 10-22, 29-35, 38-41
Y	--- NATURE, vol. 375, 11 May 1995, LONDON GB, pages 159-161, XP002039811 LUO E.A.: "Cell-cycle inhibition by independent CDK and PCNA binding domains in p21(cip1)" cited in the application See especially p.159, column 2 ✕ --- -/-	1-3, 10-22, 29-35, 38-41

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

8 September 1997

Date of mailing of the international search report

17.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Groenendijk, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ONCOGENE, vol. 12, no. 3, 1 February 1996, pages 595-607, XP002039814 CHEN E.A.: "Characterization of p21(cip1/waf1) peptide domains required for cyclin E/Cdk2 and PCNA interaction" cited in the application The whole document; see especially p.599 ---</p>	<p>1-3, 10-22, 29-35, 38-41</p>
Y	<p>EMBO JOURNAL, vol. 14, no. 3, 1995, pages 555-563, XP002039812 NAKANISHI E.A.: "Identification of the active region of the DNA synthesis inhibitory gene P21" cited in the application see the whole document ---</p>	<p>1-3, 10-22, 29-35, 38-41</p>
Y	<p>ONCOGENE, vol. 10, no. 12, 15 June 1995, pages 2281-2287, XP002039813 GOUBIN E.A.: "Identification of binding domains on the p21(cip1) cyclin-dependent kinase inhibitor" cited in the application see the whole document ---</p>	<p>1-3, 10-22, 29-35, 38-41</p>
P,X	<p>CURRENT BIOLOGY, vol. 7, no. 1, 1 January 1997, pages 71-80, XP002039815 BALL E.A.: "Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21waf1" see the whole document ---</p>	<p>1-41</p>
P,X	<p>MOL.CELL.BIOL., vol. 16, no. 9, September 1996, pages 4673-4682, XP002039987 CHEN E.A.: "Cyclin-binding motifs are essential for the function of p21(cip1)" see the whole document ---</p>	<p>1-41</p>
A	<p>CURRENT BIOLOGY, vol. 5, 1 January 1995, pages 275-282, XP000607149 WARBRICK E ET AL: "A SMALL PEPTIDE INHIBITOR OF DNA REPLICATION DEFINES THE SITE OF INTERACTION BETWEEN THE CYCLIN-DEPENDENT KINASE INHIBITOR P21WAF1 AND PROLIFERATING CELL NUCLEAR ANTIGEN" cited in the application see the whole document ---</p>	<p>1-41</p>
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/01250

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NISHINIHON JOURNAL OF UROLOGY / NISHI NIHON HIYOKIKA, vol. 5, no. 2, 1 January 1995, pages 127-156, XP000572011 MACLACHLAN T K ET AL: "CYCLINS, CYCLIN-DEPENDENT KINASES AND CDK INHIBITORS: IMPLICATIONS IN CELL CYCLE CONTROL AND CANCER" ---	1-41
A	FR 2 662 698 A (CENTRE NAT RECH SCIENT) 6 December 1991 see the whole document -----	35

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/01250

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2662698 A	06-12-91	AT 143691 T	15-10-96
		DE 69122472 D	07-11-96
		DE 69122472 T	17-04-97
		EP 0485578 A	20-05-92
		WO 9118981 A	12-12-91
		JP 5502885 T	20-05-93
